IP Library Granted Patent US 8,486,455
Granted Patent B2
US 8,486,455 · App. 12/784,304 · Granted Jul 16, 2013

Polymeric delivery formulations of leuprolide with improved efficacy

Inventors: Richard L. Dunn (Fort Collins, CO); John Steven Garrett (Fort Collins, CO); Harish Ravivarapu (Union City, CA); Bhagya L. Chandrashekar (Fort Collins, CO)
Assignee: Tolmar Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,455
App. No.
12/784,304
Granted
Jul 16, 2013
Kind
B2
Abstract

The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.

Claims (5)

1. A flowable composition suitable for use as a controlled release implant, the composition comprising: (a) a biodegradable thermoplastic copolymer of lactide and glycolide including a diol residue, wherein the copolymer has a weight average molecular weight of about 15,000 to about 45,000; (b) N-methyl-2-pyrrolidone; and (c) leuprolide acetate in an amount sufficient to reduce LHRH levels in a human.

2. The flowable composition of claim 1 , wherein the diol residue is included as a chain extender.

3. The flowable composition of claim 1 , wherein the diol is 1,6-hexanediol.

4. A biodegradable implant formed in situ, in a patient, by the steps comprising: (a) injecting the flowable composition of claim 1 within the body of the patient; and (b) allowing the N-methyl-2-pyrrolidone to dissipate to produce a solid, biodegradable implant.

5. A method of reducing serum testosterone levels in a human comprising injecting a flowable composition comprising: (a) a biodegradable thermoplastic copolymer of lactide and glycolide including a diol residue, wherein the copolymer has a weight average molecular weight of about 15,000 to about 45,000; (b) N-methyl-2-pyrrolidone; and (c) leuprolide acetate in an amount sufficient to reduce LHRH levels in a human; wherein the flowable composition is injected within a body tissue of the human so that the N-methyl-2-pyrrolidone diffuses in the body fluid of the human to cause precipitation of the copolymer of lactide and glycolide to form an in situ solid implant.

Assignments (2)
SECURITY INTEREST Recorded Oct 2, 2017
From: TOLMAR THERAPEUTICS, INC.; TOLMAR, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 043756/0502 →
CHANGE OF NAME Recorded Jun 6, 2012
From: QLT USA, INC.
To: TOLMAR THERAPEUTICS, INC.
Reel/Frame 028328/0391 →
Continuity (8)
Continuation 11643505 · Dec 21, 2006
Continuation 10872671 · Jun 21, 2004
Continuation 10373400 · Feb 24, 2003
Continuation 09711758 · Nov 13, 2000
Continuation In Part 09666174 · Sep 21, 2000
Continuation In Part 09643289 · Aug 22, 2000
Continuation 09181355 · Oct 28, 1998
Related Publication 20100226954A1 · Sep 9, 2010